Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC. The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony zaawansowany rak nerki z przerzutami (typ przezrnisty) po co najmniej jednym wcześniejszym leczeniu obejmującym immunoterapię i inne leki
- •Nowotwór musi wykazywać markier CAIX (ponad 50% komórek) w badaniu tkanki
- •Co najmniej jedno miejsce widoczne na badaniach obrazowych
- •Zdrowy stan ogólny pacjenta (ocena ECOG 0-1)
- •Wiek co najmniej 18 lat
- •Prawidłowe wyniki krwi (hemoglobina, leukocyty, płytki)
- •Prawidłowa funkcja wątroby i nerek
✗ Disqualifies
- •Nowotwór w fazie mogącej być całkowicie wyleczony operacyjnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UT MD Anderson
Houston, United States
Trial contact
Samer A Srour, MBBCH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.